Piramal Pharma Clears US FDA Inspection At Canadian Facility

Piramal Pharma Ltd said on Monday that the US Food and Drug Administration completed a general good manufacturing practices inspection at its Aurora facility in Canada between May 26 and 30.

The company told exchanges the inspection concluded successfully, with no Form 483 observations and a No Action Indicated designation.

In the pharmaceutical industry, a Form 483 lists specific observations by the US FDA that may indicate regulatory violations. Having zero observations means no violations were found.

The No Action Indicated designation confirms no objectionable conditions or practices were identified during the inspection, according to the US FDA website.